From left to right: Adam Koppel (Bain Capital Life Sciences), Mike Bozik (Knopp Biosciences CEO) and Clive Meanwell (Population Health)

No sur­ren­der: A group of mar­quee biotech play­ers bets on the $350M PhI­II res­ur­rec­tion sto­ry of a heavy­weight con­tender

Any­one read­ing Bio­gen’s press re­lease on the flat fail­ure of dex­pramipex­ole in treat­ing ALS couldn’t over­look the note of fi­nal­i­ty then R&D chief Doug Williams …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.